Elite Pharmaceuticals, Inc. (ELTP) Gross margin 2017–2026
Elite Pharmaceuticals, Inc. (ELTP) gross margin by fiscal year — reported gross profit divided by reported revenue.
50.4%FY2026 · since FY2017: 38.8% → 50.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 50.4% | +2.7 pp |
| FY2025 | 47.7% | +1.2 pp |
| FY2024 | 46.5% | -2.0 pp |
| FY2023 | 48.6% | +2.7 pp |
| FY2022 | 45.9% | -0.9 pp |
| FY2021 | 46.8% | +2.4 pp |
| FY2020 | 44.3% | +6.5 pp |
| FY2019 | 37.9% | -15.0 pp |
| FY2018 | 52.9% | +14.1 pp |
| FY2017 | 38.8% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice